Phospho-HIRA (T555) Antibody

What is HIRA and why is its phosphorylation at T555 significant?

HIRA (HIR Histone Cell Cycle Regulation Defective Homolog A) is a histone chaperone that cooperates with ASF1A to promote replication-independent chromatin assembly. It is required for the periodic repression of histone gene transcription during the cell cycle and for the formation of senescence-associated heterochromatin foci (SAHF) . Phosphorylation at threonine 555 is particularly significant as it occurs during S phase when cyclin-dependent kinase 2 (CDK2) is active, suggesting a regulatory role in cell cycle progression . This specific phosphorylation is mediated by cyclin A-cdk2 and cyclin E-cdk2 complexes in an RXL-dependent manner, marking HIRA as an in vivo substrate of these kinases .

How does Phospho-HIRA (T555) antibody differ from antibodies against total HIRA?

Phospho-HIRA (T555) antibodies specifically recognize HIRA protein only when phosphorylated at threonine 555, while total HIRA antibodies detect the protein regardless of its phosphorylation status . This specificity allows researchers to study the dynamics of HIRA phosphorylation in various cellular contexts. When conducting experiments, it's advisable to use both antibodies in parallel to calculate the ratio of phosphorylated HIRA to total HIRA, providing insight into the extent of phosphorylation rather than just presence or absence .

What applications are Phospho-HIRA (T555) antibodies suitable for?

Phospho-HIRA (T555) antibodies have been validated for several applications:

Different antibody preparations may have specific recommended dilutions, so always check the manufacturer's guidelines for optimal results.

How should I validate the specificity of a Phospho-HIRA (T555) antibody?

Validation of phospho-specific antibodies is crucial for experimental reliability. A systematic approach includes:

• Dephosphorylation assay: Treat protein lysates with bovine intestinal phosphatase and compare immunoreactivity before and after treatment. Loss of signal confirms phospho-specificity .

• Peptide competition: Pre-incubate the antibody with the phosphorylated peptide used as immunogen. This should abolish specific binding in subsequent applications .

• Kinase inhibition experiments: Treat cells with CDK2 inhibitors or express CDK inhibitor p21cip1, which should reduce HIRA T555 phosphorylation if the antibody is specific .

• Positive and negative controls: Include samples with known phosphorylation status, such as cells in different cell cycle phases (S phase should show increased T555 phosphorylation) .

• Phospho-mutant expression: Compare detection in cells expressing wild-type HIRA versus a T555A mutant that cannot be phosphorylated at this site .

What tissue/sample preparation methods optimize detection of phosphorylated HIRA?

For optimal detection of phosphorylated HIRA:

• Rapid sample processing: Phosphorylation status can change rapidly after cell lysis, so quick processing is essential.

• Phosphatase inhibitors: Always include phosphatase inhibitors in lysis buffers to preserve phosphorylation states.

• Hot lysis method: For Western blotting, a 1% SDS hot lysis method is recommended to ensure complete protein denaturation and phospho-epitope accessibility .

• Tissue fixation considerations: For IHC applications, phospho-epitopes can be sensitive to overfixation. Optimize fixation times and consider using phospho-epitope retrieval techniques.

• Storage conditions: Store samples at -80°C with phosphatase inhibitors to maintain phosphorylation status.

How can I troubleshoot non-specific bands in Western blots using Phospho-HIRA (T555) antibody?

Non-specific bands are a common challenge when working with phospho-specific antibodies:

• Optimize antibody dilution: Test a range of dilutions to find the optimal signal-to-noise ratio.

• Blocking optimization: Test different blocking agents (BSA, non-fat dry milk, commercial blockers) as some may contain phosphatases or interfere with phospho-epitope recognition.

• Increase washing stringency: More stringent washing can reduce non-specific binding.

• Peptide competition: Perform parallel blots with and without competing phospho-peptide to identify specific bands.

• Dephosphorylation controls: Treat a portion of your sample with phosphatase to identify which bands are genuinely phospho-dependent.

• Size verification: HIRA has a calculated molecular weight of approximately 111 kDa. Bands significantly different from this may represent non-specific binding or degradation products .

How does HIRA T555 phosphorylation change during cell cycle progression and cellular stress?

HIRA phosphorylation at T555 exhibits dynamic changes:

• Cell cycle dynamics: HIRA becomes phosphorylated on threonine 555 primarily during S phase when cyclin-cdk2 kinases are active . This suggests a regulatory mechanism connecting HIRA function to cell cycle progression.

• Senescence induction: During cellular senescence, HIRA localization to PML (Promyelocytic Leukemia) nuclear bodies changes, which may involve phosphorylation-dependent mechanisms. GSK-3β mediated-phosphorylation of HIRA on S697 (not T555) has been implicated in HIRA accumulation in PML bodies during senescence .

• Inflammatory stress response: Upon interferon treatment, HIRA accumulates in PML nuclear bodies through SUMO-SIM interactions . While T555 phosphorylation hasn't been directly linked to this process, phosphorylation sites adjacent to SIM motifs can affect SUMO binding affinity.

Understanding these dynamics requires time-course experiments with careful consideration of cell synchronization methods and stress induction protocols.

What is the relationship between HIRA T555 phosphorylation and its interaction with other proteins?

HIRA's functional interactions are complex and potentially regulated by phosphorylation:

• Cyclin-CDK2 binding: HIRA binds to cyclin A and E through an RXL motif, which mediates its phosphorylation at T555. This interaction is functionally similar to other known cyclin-cdk2 substrates like E2F1 .

• PML nuclear body interactions: HIRA accumulates in PML nuclear bodies under certain conditions. This interaction involves SUMO-SIM pathways and requires SP100 protein . The relationship between T555 phosphorylation and these interactions remains to be fully elucidated.

• Histone H3.3 deposition: HIRA functions as a histone chaperone for H3.3. Following interferon stimulation, HIRA and PML contribute to increased H3.3 deposition at transcriptional end sites (TES) of interferon-stimulated genes . The role of T555 phosphorylation in this process represents an important area for investigation.

Experimental approaches to study these interactions include co-immunoprecipitation with phospho-specific antibodies, proximity ligation assays, and ChIP studies comparing wild-type and phospho-mutant HIRA.

How does HIRA T555 phosphorylation contribute to chromatin remodeling and gene regulation?

The functional consequences of HIRA T555 phosphorylation on chromatin dynamics include:

• Histone gene repression: HIRA is required for periodic repression of histone gene transcription during the cell cycle . Since T555 phosphorylation occurs in S phase, it may regulate this function.

• H3.3 deposition patterns: HIRA and PML both contribute to increased long-lasting H3.3 deposition at the transcriptional end sites of interferon-stimulated genes . Investigating whether T555 phosphorylation affects this process would provide insights into gene regulation mechanisms.

• Senescence-associated heterochromatin formation: HIRA is required for the formation of senescence-associated heterochromatin foci (SAHF) and efficient senescence-associated cell cycle exit . The role of T555 phosphorylation in this process remains an open question.

Research approaches should combine ChIP-seq using phospho-HIRA antibodies with transcriptome analysis and chromatin accessibility assays to comprehensively map the impact of this modification on genome-wide chromatin states.

How can Phospho-HIRA (T555) antibodies be integrated into larger phosphoproteomic studies?

Integration strategies include:

• Phospho-protein arrays: HIRA T555 phosphorylation can be examined alongside other phosphorylated proteins using arrays based on tissue samples captured on nitrocellulose membranes with spotted antibodies . This approach allows for comparative analysis across multiple signaling pathways.

• Multiplexed immunoassays: Combine Phospho-HIRA (T555) detection with other phospho-proteins of interest using multiplexed detection systems that employ different fluorophores or chemiluminescent substrates.

• Targeted mass spectrometry: Use Phospho-HIRA antibodies for immunoprecipitation followed by mass spectrometry analysis to identify co-regulated phosphorylation events and associated proteins.

• Sequential probing strategies: For Western blots, carefully planned sequential probing with multiple phospho-specific antibodies can maximize data obtained from limited samples.

What controls are essential when using Phospho-HIRA (T555) antibody in different experimental contexts?

Essential controls include:

• Phosphatase treatment control: Always include a phosphatase-treated sample to confirm phospho-specificity .

• Total HIRA control: Parallel detection of total HIRA protein is crucial for normalizing phosphorylation levels and interpreting results correctly .

• Cell cycle controls: Since T555 phosphorylation varies throughout the cell cycle, include samples from synchronized cells at different cycle phases .

• Kinase inhibition controls: Include samples treated with CDK2 inhibitors or expressing CDK inhibitors like p21cip1 .

• Phospho-mimetic and phospho-null mutants: When possible, include cells expressing HIRA T555A (cannot be phosphorylated) and T555E/D (phospho-mimetic) variants as additional specificity controls.

How can quantitative analysis of HIRA T555 phosphorylation be optimized?

Quantitative analysis optimization approaches:

How might single-cell analysis techniques be applied to study HIRA T555 phosphorylation heterogeneity?

Emerging single-cell approaches include:

• Single-cell Western blotting: This technique allows detection of protein phosphorylation in individual cells, revealing population heterogeneity that might be masked in bulk analyses.

• Mass cytometry (CyTOF): Adaptation of phospho-specific antibodies for mass cytometry could enable multi-parameter analysis of HIRA phosphorylation alongside other cellular markers.

• Imaging mass cytometry: This approach combines the high-parameter capabilities of mass cytometry with spatial information, allowing visualization of HIRA phosphorylation patterns within tissue architecture.

• Live-cell phosphorylation sensors: Development of FRET-based sensors for HIRA T555 phosphorylation could enable real-time monitoring in living cells.

• Single-cell phosphoproteomics: Emerging mass spectrometry methods may eventually allow phosphoproteomic analysis at single-cell resolution, providing unprecedented insights into HIRA regulation.

What are the implications of HIRA T555 phosphorylation in disease contexts beyond current research?

Potential disease-relevant research directions:

• Cancer biology: Given HIRA's role in chromatin regulation and senescence, investigating T555 phosphorylation in various cancer types could reveal mechanisms of transcriptional dysregulation and cell cycle checkpoint override.

• Inflammatory disorders: HIRA's involvement in interferon responses suggests potential roles in inflammatory diseases. Examining T555 phosphorylation in these contexts could reveal novel regulatory mechanisms.

• Developmental disorders: HIRA is considered a primary candidate gene in DiGeorge syndrome, and insufficient production may disrupt normal embryonic development . Understanding the role of T555 phosphorylation in development could provide new insights.

• Aging and senescence-related conditions: Given HIRA's role in senescence-associated heterochromatin formation, investigating T555 phosphorylation in aging tissues may reveal novel therapeutic targets.

• Viral infections: Since HIRA partitioning in PML bodies occurs upon viral infection through the IFN-I signaling pathway , exploring T555 phosphorylation in this context could illuminate host-pathogen interactions.

These research directions will benefit from interdisciplinary approaches combining the Phospho-HIRA (T555) antibody with diverse methodologies spanning molecular biology, cell biology, and clinical research.